ASAP Act
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill, the Alzheimer’s Screening and Prevention Act, aims to expand Medicare coverage for blood-based tests used to detect early signs of Alzheimer’s disease and related dementias. It establishes a definition for these screening tests and outlines the types of tests that would be covered, including genomic sequencing and other blood-based analyses. The bill also adjusts Medicare payment procedures to accommodate these new screenings.
Key provisions
- Medicare will cover blood-based tests for early detection of Alzheimer’s disease and related dementias.
- The bill defines ‘Alzheimer’s disease and related dementias early detection screening tests’ to include specific types of genomic sequencing and other blood tests.
- Tests must be cleared by the FDA (under section 510(k), 513(f)(2), or 515) to be covered.
- The bill updates Medicare payment procedures to reflect the new coverage.
Who is affected
- Medicare beneficiaries
- Individuals at risk for Alzheimer’s disease
- Healthcare providers administering the screening tests
- Pharmaceutical companies developing and providing the tests
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
203 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours